Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;12(7):403-12.
doi: 10.1038/nrneurol.2016.82. Epub 2016 Jun 24.

Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management

Randi J Hagerman  1 , Paul Hagerman  2
Affiliations
Review

Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management

Randi J Hagerman et al. Nat Rev Neurol. 2016 Jul.

Abstract

Many physicians are unaware of the many phenotypes associated with the fragile X premutation, an expansion in the 5' untranslated region of the fragile X mental retardation 1 (FMR1) gene that consists of 55-200 CGG repeats. The most severe of these phenotypes is fragile X-associated tremor/ataxia syndrome (FXTAS), which occurs in the majority of ageing male premutation carriers but in fewer than 20% of ageing women with the premutation. The prevalence of the premutation is 1 in 150-300 females, and 1 in 400-850 males, so physicians are likely to see people affected by FXTAS. Fragile X DNA testing is broadly available in the Western world. The clinical phenotype of FXTAS at presentation can vary and includes intention tremor, cerebellar ataxia, neuropathic pain, memory and/or executive function deficits, parkinsonian features, and psychological disorders, such as depression, anxiety and/or apathy. FXTAS causes brain atrophy and white matter disease, usually in the middle cerebellar peduncles, the periventricular area, and the splenium and/or genu of the corpus callosum. Here, we review the complexities involved in the clinical management of FXTAS and consider how targeted treatment for these clinical features of FXTAS will result from advances in our understanding of the molecular mechanisms that underlie this neurodegenerative disorder. Such targeted approaches should also be more broadly applicable to earlier forms of clinical involvement among premutation carriers.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mov Disord. 2006 Jan;21(1):98-102 - PubMed
    1. Clin Interv Aging. 2008;3(2):251-62 - PubMed
    1. Am J Med Genet A. 2008 Apr 15;146A(8):1009-16 - PubMed
    1. Intractable Rare Dis Res. 2014 Nov;3(4):162-5 - PubMed
    1. Am J Med Genet B Neuropsychiatr Genet. 2005 Nov 5;139B(1):115-21 - PubMed

Supplementary concepts